Literature DB >> 19898686

Synthesis and Purification of Highly Hydrophobic Peptides Derived from the C-Terminus of Amyloid β-Protein.

M M Condron1, B H Monien, G Bitan.   

Abstract

Some biotechnological inventions involve expensive, sophisticated machines. Others are relatively simple innovations that nevertheless address, and solve difficult problems. Synthesis and purification of highly hydrophobic peptides can be a difficult and challenging task, particularly when these peptides have low solubility in both aqueous and organic solvents. Here we describe the synthesis and purification of a series of peptides derived from the hydrophobic C-terminus of the 42-residue form of amyloid β-protein (Aβ42), a peptide believed to be the primary cause for Alzheimer's disease (AD). The series of C-terminal fragments (CTFs) had the general formula Aβ(x-42), x=28-39, which potentially can be used as inhibitors of Aβ42 assembly and neurotoxicity. Synthesis and purification of peptides containing 8-residues or less were straightforward. However, HPLC purification of longer peptides was problematic and provided <1% yield in particularly difficult cases due to very poor solubility in the solvent systems used both in reverse- and in normal phase chromatography. Modification of the purification protocol using water precipitation followed by removal of scavengers by washing with diethyl ether circumvented the need for HPLC purification and provided these peptides with purity as high as HPLC-purified peptides and substantially increased yield.

Entities:  

Year:  2008        PMID: 19898686      PMCID: PMC2773559          DOI: 10.2174/1874070700802010087

Source DB:  PubMed          Journal:  Open Biotechnol J


  39 in total

1.  In silico study of amyloid beta-protein folding and oligomerization.

Authors:  B Urbanc; L Cruz; S Yun; S V Buldyrev; G Bitan; D B Teplow; H E Stanley
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-06       Impact factor: 11.205

Review 2.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

3.  On the nucleation of amyloid beta-protein monomer folding.

Authors:  Noel D Lazo; Marianne A Grant; Margaret C Condron; Alan C Rigby; David B Teplow
Journal:  Protein Sci       Date:  2005-06       Impact factor: 6.725

4.  Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.

Authors:  Fusheng Yang; Giselle P Lim; Aynun N Begum; Oliver J Ubeda; Mychica R Simmons; Surendra S Ambegaokar; Pingping P Chen; Rakez Kayed; Charles G Glabe; Sally A Frautschy; Gregory M Cole
Journal:  J Biol Chem       Date:  2004-12-07       Impact factor: 5.157

5.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease.

Authors:  Stefan Barghorn; Volker Nimmrich; Andreas Striebinger; Carsten Krantz; Patrick Keller; Bodo Janson; Michael Bahr; Martin Schmidt; Robert S Bitner; John Harlan; Eve Barlow; Ulrich Ebert; Heinz Hillen
Journal:  J Neurochem       Date:  2005-08-31       Impact factor: 5.372

7.  Economic cost of Alzheimer disease in Israel.

Authors:  Michal Schnaider Beeri; Perla Werner; Zvi Adar; Michael Davidson; Shlomo Noy
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Apr-Jun       Impact factor: 2.703

8.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

Authors:  N Suzuki; T T Cheung; X D Cai; A Odaka; L Otvos; C Eckman; T E Golde; S G Younkin
Journal:  Science       Date:  1994-05-27       Impact factor: 47.728

Review 9.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

10.  Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.

Authors:  Karie N Dahlgren; Arlene M Manelli; W Blaine Stine; Lorinda K Baker; Grant A Krafft; Mary Jo LaDu
Journal:  J Biol Chem       Date:  2002-06-10       Impact factor: 5.157

View more
  13 in total

1.  A two-step strategy for structure-activity relationship studies of N-methylated aβ42 C-terminal fragments as aβ42 toxicity inhibitors.

Authors:  Huiyuan Li; Reeve Zemel; Dahabada H J Lopes; Bernhard H Monien; Gal Bitan
Journal:  ChemMedChem       Date:  2012-02-03       Impact factor: 3.466

2.  Different Inhibitors of Aβ42-Induced Toxicity Have Distinct Metal-Ion Dependency.

Authors:  Ashley J Mason; Ian Hurst; Ravinder Malik; Ibrar Siddique; Inna Solomonov; Irit Sagi; Frank-Gerrit Klärner; Thomas Schrader; Gal Bitan
Journal:  ACS Chem Neurosci       Date:  2020-07-07       Impact factor: 4.418

3.  Production of a de-novo designed antimicrobial peptide in Nicotiana benthamiana.

Authors:  Benjamin Zeitler; Antonie Bernhard; Helge Meyer; Michael Sattler; Hans-Ulrich Koop; Christian Lindermayr
Journal:  Plant Mol Biol       Date:  2012-12-16       Impact factor: 4.076

Review 4.  Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity.

Authors:  Huiyuan Li; Farid Rahimi; Gal Bitan
Journal:  ACS Chem Neurosci       Date:  2016-07-05       Impact factor: 4.418

5.  Mechanistic investigation of the inhibition of Abeta42 assembly and neurotoxicity by Abeta42 C-terminal fragments.

Authors:  Huiyuan Li; Bernhard H Monien; Aleksey Lomakin; Reeve Zemel; Erica A Fradinger; Miao Tan; Sean M Spring; Brigita Urbanc; Cui-Wei Xie; George B Benedek; Gal Bitan
Journal:  Biochemistry       Date:  2010-08-03       Impact factor: 3.162

6.  C-terminal tetrapeptides inhibit Aβ42-induced neurotoxicity primarily through specific interaction at the N-terminus of Aβ42.

Authors:  Huiyuan Li; Zhenming Du; Dahabada H J Lopes; Erica A Fradinger; Chunyu Wang; Gal Bitan
Journal:  J Med Chem       Date:  2011-11-28       Impact factor: 7.446

7.  Biophysical characterization of Abeta42 C-terminal fragments: inhibitors of Abeta42 neurotoxicity.

Authors:  Huiyuan Li; Bernhard H Monien; Erica A Fradinger; Brigita Urbanc; Gal Bitan
Journal:  Biochemistry       Date:  2010-02-16       Impact factor: 3.162

8.  The structure of Abeta42 C-terminal fragments probed by a combined experimental and theoretical study.

Authors:  Chun Wu; Megan M Murray; Summer L Bernstein; Margaret M Condron; Gal Bitan; Joan-Emma Shea; Michael T Bowers
Journal:  J Mol Biol       Date:  2009-01-23       Impact factor: 5.469

9.  C-terminal peptides coassemble into Abeta42 oligomers and protect neurons against Abeta42-induced neurotoxicity.

Authors:  Erica A Fradinger; Bernhard H Monien; Brigita Urbanc; Aleksey Lomakin; Miao Tan; Huiyuan Li; Sean M Spring; Margaret M Condron; Luis Cruz; Cui-Wei Xie; George B Benedek; Gal Bitan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

10.  Novel cell-penetrating-amyloid peptide conjugates preferentially kill cancer cells.

Authors:  John R Veloria; Luxi Chen; Lin Li; Gail A M Breen; Jiyong Lee; Warren J Goux
Journal:  Medchemcomm       Date:  2017-12-05       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.